Event Detail
Post Approval Drug Safety Strategies
November 3 - 4, 2009
- Philadelphia PA UNITED STATES
Cambridge Healthtech Institute
Improving products’ clinical safety will increase the industry’s fundamental value proposition to patients, healthcare providers, payors and regulators. The program will focus on pharmacovigilance program implementation and specific strategies and approaches to creating true value from a peri- and post-approval drug safety program. The approach of this conference is not to look at safety in the silos of early-phase safety or post-approval safety but to view safety holistically, across the lifecycle, especially at the transition from approval to broader use in the marketplace. The special, three-day executive forum entitled “Post-Approval Drug Safety Strategies: Best Practices to Assess and Mitigate Risks throughout the Product’s Life Cycle” will tackle many of the pressing issues that executives are facing today.